Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02711

CAR T Cells beyond cancer: Hope for immunomodulatory therapy of infectious diseases

 Michelle Seif1, Hermann Einsele1 and  Juergen Loeffler1*
  • 1Universitätsklinikum Würzburg, Germany

Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients.
Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/ Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases.
Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.

Keywords: infectious diseases, mAb engineering, CAR T cells, HIV - human immunodeficiency virus, HBV - hepatitis B virus, HCV ( Hepatitis C), CMV (citomegalovirus), Invasive aspergillois

Received: 17 Sep 2019; Accepted: 05 Nov 2019.

Copyright: © 2019 Seif, Einsele and Loeffler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Juergen Loeffler, Universitätsklinikum Würzburg, Würzburg, Germany, Loeffler_J@ukw.de